[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [HEALTH]

112 clusters · 548 sources · 167 days · First seen · Last updated

Novo Nordisk pivots strategy to counter patent cliff

Overview

Novo Nordisk is implementing a strategic reset to address long-term growth concerns and the looming patent expiration of semaglutide in the early 2030s. To diversify its portfolio and counter competition from Eli Lilly, the company is prioritizing next-generation obesity treatments, such as the CagriSema combination therapy, and expanding its oral medication pipeline.

The company has successfully transitioned toward oral therapies, with the Wegovy pill capturing 90% of the oral obesity market in the U.S. and launching in Germany. To support this, Novo Nordisk aims to increase oral GLP-1 production tenfold to serve 15 million patients by 2030. Real-world data from the OCTANE study suggests oral semaglutide is a viable alternative for patients switching from injectables, maintaining weight loss and high satisfaction.

To bolster its pipeline, Novo Nordisk has entered several strategic licensing agreements. This includes a deal worth up to $1.33 billion with Swedish biotech Nanexa to utilize PharmaShell technology, which aims to extend dosing intervals from weekly to monthly or quarterly injections. Additionally, the company secured global rights for HRS-1596, a GLP-1 and GIP dual agonist from China’s Hengrui Pharma, which could potentially be administered as a once-weekly oral pill.

Despite clinical successes, such as the STEP Young study showing semaglutide significantly reduces obesity in children aged 6 to 12, the company faces intense competition. While CagriSema has shown results outperforming Eli Lilly’s Tirzepatide in certain metrics, Novo Nordisk’s shares have declined by approximately one-third over the past year due to the rise of Mounjaro and Zepbound, as well as the emergence of cheaper generics in markets like India and Canada.

Entities

Novo Nordisk · Eli Lilly · Wegovy · semaglutide · Mike Doustdar

Claims

What the coverage asserts, and how many sources carry each claim.

Coverage disagrees

Sources make claims that cannot both be true. CLSTR reports the disagreement; it does not decide who is right.

  • "Novo Nordisk Q2 2026 adjusted sales were 78.49 billion Danish kroner, up 7 % YoY."

    vs

    "Novo Nordisk's Q2 adjusted sales were 78.49 billion Danish kroner, up 7 % YoY."

    One claim refers to Q2 sales generally, while the other specifies Q2 2026, which is a future date inconsistent with current reporting.

  • "Novo Nordisk shares fell between 7% and 8% following the Capital Markets Day."

    vs

    "Novo Nordisk shares fell about 5‑6 % after the earnings release."

    The claims provide different percentage ranges for the fall in Novo Nordisk shares (7-8% vs 5-6%).

  • "Novo Nordisk cut about 9,000 jobs as part of a restructuring plan."

    vs

    "Novo Nordisk has reduced its global workforce by 13,000 employees from its peak."

    The claims assert different numbers for workforce reductions (9,000 jobs vs 13,000 employees).

Timeline

  1. [BUSINESS] 3 sources
    Novo Nordisk faces intense competition in obesity drug market

    Novo Nordisk faces market share losses to Eli Lilly and competition from generic drugs, making the success of its new pipeline, including CagriSema, critical for future growth.

  2. [BUSINESS] 2 sources
    Novo Nordisk faces market challenges and patent expirations

    Danish pharmaceutical leader Novo Nordisk faces market value losses and upcoming 2032 patent expirations despite progress on its next-generation obesity and diabetes drug, CagriSema.

  3. [BUSINESS] 7 sources
    Novo Nordisk expands obesity drug reach through oral treatments and insurance bids

    Novo Nordisk is scaling oral obesity drug production to reach 15 million patients by 2030 while seeking insurance reimbursement for Wegovy in South Korea to compete with Eli Lilly and local rivals.

  4. [HEALTH] 2 sources
    Novo Nordisk semaglutide study shows obesity reduction in children

    A phase 3 study shows that semaglutide combined with lifestyle changes helped 40.4% of children with obesity reach a lower weight category over 68 weeks.

  5. [BUSINESS] 8 sources
    Novo Nordisk secures major licensing deals for obesity and diabetes drugs

    Novo Nordisk has secured major licensing deals, including a $2.6 billion agreement with China's Hengrui Pharma for an oral obesity drug and a $1.3 billion deal with Sweden's Nanexa for advanced drug delivery.

  6. [BUSINESS] 18 sources
    Novo Nordisk signs $1.3 billion deal with Nanexa for long-acting drug technology

    Novo Nordisk signed a licensing deal worth up to $1.33 billion with Swedish firm Nanexa to use its PharmaShell technology for long-acting obesity and diabetes injectables.

  7. [BUSINESS] 26 sources
    Novo Nordisk faces investor pressure over growth strategy and patent cliff

    Novo Nordisk shares fell sharply after its Capital Markets Day as investors weighed ambitious 2030 growth targets against the upcoming semaglutide patent cliff and rising competition from Eli Lilly.

  8. [BUSINESS] 17 sources
    Novo Nordisk unveils 2030 growth strategy amid share price decline

    Novo Nordisk shares fell up to 9% following a Capital Markets Day in London, where the company announced plans to launch five multi-blockbuster drugs by 2030 and expand its oral obesity therapy production.

  9. [BUSINESS] 3 sources
    Novo Nordisk reports pediatric obesity trial success amid market pressure

    Novo Nordisk faces stock underperformance and competitive pressure, but recent phase 3 trials for semaglutide show significant success in treating pediatric obesity.

  10. [BUSINESS] 4 sources
    Morgan Stanley and Bank of America downgrade Novo Nordisk and DNB Bank

    Morgan Stanley downgraded Novo Nordisk to ‘Underweight’ due to growth concerns and patent risks, while Bank of America downgraded DNB Bank to ‘Underperform’ citing competition and margin pressure.

  11. [BUSINESS] 6 sources
    Novo Nordisk expands obesity drug market in Mexico

    Novo Nordisk expands in Mexico with oral obesity treatments, while GLP-1 medication use begins to shift consumer habits by reducing high-calorie food purchases.

  12. [BUSINESS] 4 sources
    Novo Nordisk expands obesity drug portfolio with Wegovy pill launch

    Novo Nordisk is strengthening its obesity drug market position through new patents and the launch of the Wegovy pill in Germany, the first oral GLP-1 therapy available in the EU.

  13. [BUSINESS] 2 sources
    Novo Nordisk faces mixed analyst ratings and growth concerns

    Analysts provide mixed outlooks for Novo Nordisk, with Deutsche Bank downgrading the stock to ‘sell’ due to growth concerns, while Erste Group Bank raised its FY2026 earnings estimates.

  14. [HEALTH] 36 sources
    Novo Nordisk launches Wegovy weight-loss pill in Germany

    Novo Nordisk has launched the Wegovy weight-loss pill in Germany, providing an oral semaglutide alternative to weekly injections for treating obesity.

  15. [BUSINESS] 2 sources
    Novo Nordisk expands obesity drug market share via Wegovy pill

    Novo Nordisk is strengthening its position in the obesity drug market through Wegovy's oral pill expansion and a robust pipeline including CagriSema to compete with Eli Lilly.

  16. [BUSINESS] 5 sources
    Novo Nordisk begins Phase 3 trial for lower-dose Wegovy pill

    Novo Nordisk has begun a Phase 3 study lasting until 2028 to test lower doses of its oral Wegovy pill for weight loss in 450 adults.

  17. [HEALTH] 6 sources
    Semaglutide tablets to launch in Germany amid new metabolic research

    Semaglutide tablets are set to launch in German pharmacies this September, while new research suggests the drug also works by mobilizing energy from fat stores rather than just suppressing appetite.

  18. [HEALTH] 16 sources
    Wegovy weight-loss tablets to launch in Germany this September

    Novo Nordisk will launch Wegovy weight-loss tablets in Germany on September 1, offering an oral alternative to injections for obesity treatment, amid medical warnings regarding unregulated online sellers.

  19. [BUSINESS] 2 sources
    Novo Nordisk raises 2026 outlook as oral Wegovy prescriptions top 5 million

    Novo Nordisk raised its 2026 outlook following strong Q2 sales, driven by the rapid growth of oral Wegovy, which has surpassed 5 million prescriptions in the U.S.

  20. [BUSINESS] 15 sources
    Novo Nordisk lifts 2025 outlook despite Wegovy pill miss

    Novo Nordisk posted Q2 sales of 78.5 bn DKK, raised its 2025 outlook to a max 6 % decline, but Wegovy oral sales missed forecasts and CagriSema trial fell short; shares slid 5‑6 % and a 0.5786 DKK dividend was

  21. [BUSINESS] 19 sources
    Novo Nordisk lifts outlook as oral Wegovy sales boost earnings

    Novo Nordisk beat Q2 profit forecasts, raised its outlook, and saw Wegovy drive a 35% share rise, while a failed ZEUS study and a lawsuit against Eli Lilly add pressure.

  22. [HEALTH] 2 sources
    European Commission approves oral semaglutide pill for obesity treatment

    EU regulators approved a 25 mg oral semaglutide tablet for adult obesity, the first oral GLP‑1 drug in Europe, showing up to 17‑22% weight loss in trials and similar safety to injectables.

  23. [HEALTH] 9 sources
    US Medicare Launches GLP-1 Bridge Program to Cut Drug Costs

    GLP‑1 drugs aid diabetes, obesity and may improve psoriasis but carry eye‑risk warnings. CMS launched a Medicare Bridge Program on July 1, offering selected GLP‑1 meds for $50/month to eligible users through  7

  24. [BUSINESS] 8 sources
    Novo Nordisk Seeks Injunction Against Eli Lilly's GLP-1 Advertising Amid Stock Buy Rating

    Novo Nordisk filed a US injunction to block Eli Lilly's GLP‑1 ads over alleged misleading claims, while analysts initiated a BUY rating with a $68 target, citing growth in obesity treatments and pipeline assets

  25. [HEALTH] 2 sources
    EU Commission approves Novo Nordisk's oral weight‑loss pill

    The EU Commission approved Novo Nordisk's 25 mg oral semaglutide pill for obesity and overweight, citing trial data showing 17 % average weight loss and a 20 % cut in major cardiovascular events.

  26. [HEALTH] 3 sources
    Medicare GLP-1 Bridge Program Set to End 2027, Threatening Access for Seniors

    The Medicare GLP-1 Bridge program, offering seniors $50 copays for weight‑loss drugs, ends Dec 2027, leaving millions at risk of losing affordable access amid broader insurer cutbacks and supply shortages.

  27. [BUSINESS] 5 sources
    Novo Nordisk Sues Eli Lilly Over GLP‑1 Dosage Advertising Dispute

    Novo Nordisk sued Eli Lilly in US federal court, claiming the rival’s GLP‑1 drug ads mislead about dosage differences and seeking ad removal and damages.

  28. [BUSINESS] 4 sources
    Novo Nordisk's oral GLP‑1 weight‑loss pill gets EU approval amid strict European ad rules

    EU regulators approved Novo Nordisk's first oral semaglutide weight‑loss pill, while strict European ad rules contrast with the US's permissive advertising environment.

  29. [HEALTH] 2 sources
    Novo Nordisk and Global Weight‑Loss Drug Advertising Restrictions

    Most countries bar direct ads for prescription weight‑loss drugs like Novo Nordisk’s Ozempic and Wegovy; only the US and New Zealand permit such advertising due to free‑speech protections.

  30. [BUSINESS] 40 sources
    Novo Nordisk sues Eli Lilly over alleged false advertising of weight‑loss drugs

    Novo Nordisk sued Eli Lilly in New Jersey, alleging its ads compare Lilly’s drugs to lower‑dose Wegovy/Ozempic and mislead consumers, seeking injunctions and damages amid a $100 bn GLP‑1 market fight.

  31. [HEALTH] 2 sources
    Semaglutide generic approvals boost access in Canada and South Africa

    Health Canada approved Aspen's generic semaglutide while Novo Nordisk launched an authorised Ozempic copy in South Africa, both aimed at expanding access as patents expire and supply challenges linger.

  32. [HEALTH] 2 sources
    Novo Nordisk's oral Wegovy tablet tops 3 million US prescriptions and wins EU approval

    Novo Nordisk’s oral Wegovy tablet logged over 3 million U.S. prescriptions in six months and secured EU approval for 27 members, expanding its market amid rising competition with Eli Lilly.

  33. [HEALTH] 11 sources
    Semaglutide and GLP-1 drugs show health benefits and risks globally

    Studies link semaglutide and other GLP‑1 drugs to lower cancer and dementia risks, while noting rare eye side effects; generic versions appear in Canada, a new oral pill launches in the UK, and US GLP‑1 use for

  34. [HEALTH] 8 sources
    EU Approves First Oral GLP‑1 Weight‑Loss Pill, Wegovy Tablet

    The EU has approved Wegovy oral semaglutide, the first GLP‑1 weight‑loss tablet, based on trials showing ~13‑17% weight loss; launch slated for Q3 2026, while food firms like Nestlé adapt products for GLP‑1‑twe

  35. [HEALTH] 2 sources
    India Approves Novo Nordisk's Wegovy for Fatty Liver Disease Treatment

    India's CDSCO approved Novo Nordisk's Wegovy injection for treating metabolic dysfunction‑associated steatohepatitis (MASH), marking the first GLP‑1 drug approved for this condition in the country.

  36. [HEALTH] 5 sources
    Brazilian Consumers Face Up to 25‑Fold Drug Price Gaps

    Brazil's drug market shows stark price gaps, with a study revealing up to 25‑fold differences across pharmacies and a new semaglutide pen price cut aiming to improve access.

  37. [HEALTH] 2 sources
    Greek Health Minister Georgiadis to fund free obesity drugs

    Greek Health Minister Georgiadis will fund free adult obesity drugs from the state budget after EU funds ran out, with a solution expected within 15 days to cover ~43,500 beneficiaries.

  38. [HEALTH] 24 sources
    Novo Nordisk's Wegovy oral tablet receives EU approval

    EU regulators approve Novo Nordisk's Wegovy oral semaglutide tablet for obesity, showing ~17% weight loss and cardiovascular benefit; daily use with diet and exercise.

  39. [HEALTH] 9 sources
    Brazil expands access to modern diabetes drugs, including insulin glargina and Ozivy

    Brazil's SUS is expanding insulin glargina distribution to children, adolescents and seniors, while EMS cuts Ozivy prices to R$10 a day, boosting access to modern diabetes treatments.

  40. [HEALTH] 4 sources
    Medical AI and Semaglutide Implant Highlight Health Tech Advances in Brazil and Canada

    A Brazil lecture will discuss AI and digital tools in medicine, while a Canadian firm develops a six‑month semaglutide implant to improve obesity and diabetes treatment adherence.

  41. [HEALTH] 3 sources
    Vivani Medical's NPM-139 semaglutide implant begins early human trials for obesity and type‑2 diabetes

    Vivani Medical’s NPM-139 semaglutide implant, developed with Novo Nordisk, starts early human trials to deliver a year‑long obesity and type‑2 diabetes therapy, aiming to improve adherence over weekly injectors

  42. [HEALTH] 4 sources
    Obesity patients confront weight‑regain despite surgery and new therapies

    Obesity is chronic; weight‑regain after bariatric surgery affects 20‑30% of patients, prompting combined endoscopic and GLP‑1 treatments with ongoing multidisciplinary care.

  43. [HEALTH] 4 sources
    Greek obesity expert says stopping treatment causes weight regain

    Greek endocrinologist warns stopping obesity treatment leads to weight regain and urges continued therapy despite funding concerns.

  44. [HEALTH] 3 sources
    Wegovy weight‑loss drug shows stronger safety signal for rare vision loss as UK rolls out oral pill

    Study of FDA data finds Wegovy has a five‑fold stronger safety signal for rare vision‑loss condition NAION, while the UK launches a daily oral Wegovy pill with strict dosing rules.

  45. [HEALTH] 2 sources
    Novo Nordisk launches Brazil digital pharmacy and brings Wegovy to Peru

    Novo Nordisk opened Brazil’s NovoCare Farmácia digital pharmacy for Ozempic, Wegovy and Rybelsus, and launched Wegovy in Peru with its Vive Ligero campaign, expanding obesity and diabetes treatment access in L

  46. [HEALTH] 2 sources
    Novo Nordisk to assess Vivani's year‑long semaglutide implant for obesity maintenance

    Novo Nordisk will evaluate Vivani Medical's NPM‑139 semaglutide implant, a year‑long device intended to improve obesity treatment adherence, with a Phase 1 trial slated for mid‑2026.

  47. [HEALTH] 2 sources
    China adds semaglutide to essential drug list, expanding diabetes care

    China will list semaglutide on its essential drug list from Sept 1, boosting nationwide diabetes treatment access and opening the market to generics.

  48. [BUSINESS] 2 sources
    Novo Nordisk launches new Wegovy variant in Singapore amid obesity‑drug competition

    Novo Nordisk has introduced a 7.2 mg Wegovy formulation in Singapore, aiming to keep its first‑mover edge in the obesity market as competition from Eli Lilly intensifies and overall sales pressure grows.

  49. [HEALTH] 6 sources
    Semaglutide weight‑loss drugs face safety warnings amid misuse concerns

    Health officials across South Africa, Argentina, Chile, the US and Mexico warn that rising off‑label use of semaglutide for weight loss brings safety risks, urging medical supervision and regulated supply.

  50. [HEALTH] 13 sources
    UK launches oral Wegovy weight‑loss pill, pricing similar to injection

    The oral Wegovy weight‑loss pill launched in the UK, priced £98‑£200/month, offering a needle‑free alternative and drawing strong consumer interest.

  51. [HEALTH] 3 sources
    Germany’s surge in GLP‑1 weight‑loss drugs and pending oral semaglutide approval

    Germany’s use of GL‑1 weight‑loss injectables surges, prompting warnings over illegal prescriptions, while an oral semaglutide pill awaits EU approval after U.S. clearance.

  52. [HEALTH] 2 sources
    Brazil's Eurofarma‑Novo Nordisk program slashes obesity pen prices

    Eurofarma and Novo Nordisk's EuroCuida program cuts Brazil's Poviztra and Extensior pen prices, while the Reciclaneta recycling scheme reaches 100 collection points and 120k pens.

  53. [HEALTH] 2 sources
    US Medicare launches GLP-1 Bridge program for weight‑loss drugs

    Medicare’s new GLP‑1 Bridge pilot lets eligible seniors access weight‑loss drugs like Wegovy for $50 a month, aiming to curb obesity‑related health costs.

  54. [HEALTH] 4 sources
    Health Canada authorizes first generic semaglutide injection for weight loss

    Health Canada approved Apotex's generic semaglutide injection Svemia for weight loss in people 12+, the first such product, joining two diabetes generics and with six more submissions under review.

  55. [HEALTH] 2 sources
    Novo Nordisk Medicare Coverage Expands Wegovy to 3.8 Million US Seniors

    Medicare will cover Novo Nordisk’s obesity drug Wegovy for up to 3.8 million seniors from July 2026 with a $50 copay, but most beneficiaries are unaware of the new Bridge program.

  56. [HEALTH] 2 sources
    Brazil's SUS Begins Semaglutide Trial and Opens First Smart ICU

    Brazil's SUS starts a semaglutide trial for severe obesity and opens its first AI‑driven smart ICU, marking major health‑system innovations.

  57. [HEALTH] 2 sources
    Brazil's SUS drug access challenged by court delays and new obesity medication study

    Brazil finds most court‑sought drugs already approved for SUS yet delayed, while a new study tests semaglutide for obesity to inform possible public‑health inclusion.

  58. [HEALTH] 2 sources
    Brazil's Health Ministry Launches Semaglutide Pilot for Obesity Treatment in SUS

    Brazil's health ministry started a two‑year semaglutide pilot in SUS, enrolling 250 obese patients at a Rio Grande do Sul hospital to assess weight loss, quality of life and costs; the drug is not yet publicly‑

  59. [HEALTH] 2 sources
    Novo Nordisk introduces new obesity treatments in the Dominican Republic

    Novo Nordisk launches Wegovy injectable and an oral semaglutide pill in the Dominican Republic, targeting a population where 68% are overweight and promoting a support programme for obesity treatment.

  60. [HEALTH] 2 sources
    Greece faces two‑month drug shortage for obesity patients

    Around 71,000 Greeks on the Recovery Fund’s obesity drug programme face a two‑month gap when it ends June 30, leaving them without Mounjaro or Wegovy until national funding begins on Sept 1, risking weight‑reg­

  61. [HEALTH] 13 sources
    Brazil's Health Ministry launches semaglutide pilot for obesity treatment in SUS

    Brazil’s Health Ministry launched a two‑year SUS pilot in Rio Grande do Sul, giving semaglutide to 250 severe‑obesity patients to evaluate weight loss, health outcomes and cost for possible public use.

  62. [HEALTH] 3 sources
    Eli Lilly's experimental weight‑loss drug retatrutide shows major weight loss in trials

    Eli Lilly's experimental drug retatrutide, a triple‑hormone agonist, caused up to 24 % body‑weight loss in Phase 3 trials but is not FDA‑approved, with mild GI side effects and FDA cautions.

  63. [HEALTH] 3 sources
    Novo Nordisk proposes 59% discount for semaglutide in Brazil's SUS

    Novo Nordisk has offered a 59% discount on semaglutide to introduce the obesity drug into Brazil's public health system for high‑risk patients, after a previous costly proposal was rejected.

  64. [BUSINESS] 7 sources
    Eli Lilly plans European launch of obesity pill, U.S. MFN pricing may shape rollout

    Eli Lilly will launch its obesity drug Orforglipron in Europe/UK in late 2026, focusing on telehealth and public reimbursement, while U.S. MFN pricing policy may affect pricing. A phase‑3 trial showed 28 % avg.

  65. [HEALTH] 2 sources
    US patients face insurance cuts to GLP-1 weight‑loss drugs

    US insurers are dropping coverage for GLP‑1 weight‑loss drugs like Zepbound and Wegovy, affecting millions; patients can appeal by documenting qualifying health conditions and using prior authorizations.

  66. [HEALTH] 8 sources
    Brazil's Health Ministry to Study GLP‑1 Weight‑Loss Drugs for SUS

    Brazil's health ministry will test GLP‑1 weight‑loss drugs in 250 super‑obese patients to assess clinical and economic benefits for SUS, while encouraging local production to cut prices.

  67. [HEALTH] 2 sources
    UK approves first daily oral GLP-1 weight-loss pill

    UK’s MHRA approved Novo Nordisk’s daily oral semaglutide pill, the first GLP‑1 tablet for obesity, pending private‑market launch and not yet NHS‑covered.

  68. [HEALTH] 5 sources
    Eurofarma slashes Brazil obesity and diabetes pen prices by up to 48%

    Eurofarma announced up to 48% cuts on its semaglutide pens Poviztra (obesity) and Extensior (diabetes) in Brazil, with 1 mg doses falling to R$309 and other doses receiving 40‑46% discounts under its EuroCuida

  69. [BUSINESS] 2 sources
    Eli Lilly accelerates acquisitions as weight‑loss drug Retatrutide cuts weight by 28%

    Eli Lilly announced 13 acquisitions in 2026 and reported Retatrutide’s phase‑3 trial cut participants’ weight by 28.3% (70 lb). Q1 sales rose 55.5% to $19.8 bn while German investment was cut.

  70. [HEALTH] 2 sources
    GLP-1 obesity drugs in focus as Medicare pilot launches and Swiss biotech research emerges

    Medicare will roll out a $50‑per‑month GLP‑1 weight‑loss pilot in the US, while Swiss biotech MetaShape reports early data that its MS 001 may boost GLP‑1 effectiveness by sparing muscle and increasing fat burn

  71. [HEALTH] 2 sources
    Anvisa clears Cristália's semaglutide weight‑loss pen produced in China

    Anvisa approved Cristália’s semaglutide weight‑loss pen, to be made in China with plans for Brazilian market debut in 2026 and local production transfer by 2028.

  72. [HEALTH] 2 sources
    ADA 2026 conference reports breakthrough combo drug CagriSema for type‑2 diabetes

    ADA 2026 in New Orleans unveiled CagriSema, a cagrilintide‑semaglutide combo that cut HbA1c and delivered up to 14 % weight loss, while confirming semaglutide is a synthetic GLP‑1 drug used for diabetes and ob‑

  73. [HEALTH] 4 sources
    Brazil's EMS launches Ozivy, first domestically produced semaglutide pen

    EMS launches Ozivy, Brazil's first semaglutide pen for type 2 diabetes, priced at R$452 (R$287 with discount) after ANVISA approval; 500 k units released nationwide.

  74. [HEALTH] 3 sources
    France begins reimbursing Wegovy and Mounjaro anti‑obesity treatments

    France starts reimbursing 65 % of Wegovy and Mounjaro for eligible obese patients, limiting prescriptions to specialized centers and projecting €100 million in annual costs.

  75. [HEALTH] 6 sources
    France to reimburse Wegovy and Mounjaro for obesity treatment starting Monday

    France will reimburse 65% of Wegovy and Mounjaro for eligible obesity patients from Monday, covering up to one million people and costing an estimated €100 million by 2027.

  76. [HEALTH] 3 sources
    Brazil's Hospital da Criança de Brasília adopts liraglutide for adolescent obesity treatment

    HCB in Brazil uses liraglutide, a Ministry‑approved GLP‑1 drug, to treat adolescent obesity alongside nutrition, psychology and other specialties.

  77. [HEALTH] 2 sources
    UK approves first oral GLP‑1 weight‑loss pill, prompting massive consumer interest

    The UK’s MHRA has approved oral semaglutide, the first tablet GLP‑1 weight‑loss drug, sparking over 70,000 sign‑ups; the £99‑a‑month pill offers ~14% weight loss in 64 weeks and awaits NHS approval.

  78. [BUSINESS] 2 sources
    Novo Nordisk opens Czech obesity‑drug plant in Bohumil

    Novo Nordisk opened a 300‑person plant in Bohumil, Czech Republic, investing over 8 bn CZK to produce obesity and diabetes medicines for local use and export, marking a strategic boost to Czech pharma self‑suff

  79. [HEALTH] 2 sources
    Semaglutide combinations and oral form improve blood sugar and weight in new studies

    New studies find weekly cagrilintide‑semaglutide injections and oral semaglutide both lower HbA1c, aid weight loss, and improve metabolic markers in type 2 diabetes patients.

  80. [HEALTH] 3 sources
    UK Approves First Oral GLP-1 Weight‑Loss Pill

    The UK’s MHRA approved semaglutide (Wegovy) tablets—the first oral GLP‑1 weight‑loss pill—available privately for adults with obesity, pending NHS review.

  81. [HEALTH] 3 sources
    UK regulator approves Wegovy weight‑loss tablet for private prescription

    The UK MHRA has approved Wegovy's oral semaglutide tablet for private prescription, targeting adults with obesity (BMI ≥ 30 or 27‑30 with a health condition). It is not yet NHS‑covered and is expected to spur a

  82. [HEALTH] 2 sources
    UK approves Novo Nordisk's Wegovy oral weight‑loss tablet

    UK regulators approved Novo Nordisk's Wegovy oral tablet, the first in Europe, for private prescription to treat obesity; NHS rollout pending NICE approval.

  83. [HEALTH] 2 sources
    Experimental drug survodutida cuts liver fat by up to 70% in phase‑3 trial

    Phase‑3 trial of survodutida in the US and Spain shows up to 70% liver‑fat reduction and cardiovascular benefits in obese patients, though longer studies are needed.

  84. [HEALTH] 2 sources
    France to reimburse anti‑obesity drugs as Italy urges comparable access

    France will start reimbursing tirzepatide and semaglutide for severe obesity on 15 June, prompting Italy’s obesity society to call for a similar, sustainable access plan under Law 149/2025.

  85. [BUSINESS] 2 sources
    Brazil sees new semaglutide pen launch and upbeat Pague Menos stock outlook

    Ávita Care aims to launch a new semaglutide weight‑loss pen in Brazil by June, while Safra Bank lowers Pague Menos' price target but predicts a 66% share rise.

  86. [HEALTH] 2 sources
    HK inno.’s ecnoglutide outperforms semaglutide in obesity trial

    HK inno.’s obesity drug ecnoglutide cut weight 35% more than semaglutide in a 20‑week phase‑2 trial of 163 Chinese patients, with twice as many achieving ≥10% loss and better tolerability.

  87. [BUSINESS] 2 sources
    Novo Nordisk pursues longevity and aesthetic medicine as it diversifies beyond obesity drugs

    Novo Nordisk seeks to broaden its portfolio into longevity and aesthetic medicine after its stock fell, highlighting semaglutide’s potential organ‑protective effects beyond weight loss.

  88. [HEALTH] 2 sources
    Eli Lilly's experimental weight‑loss drug retatrutide shows strong trial results, fuels US demand despite lack of FDA OK

    Eli Lilly’s experimental GLP‑1 drug retatrutide posted up to 30% weight loss in Phase 3 trials, boosting its stock and sparking U.S. demand despite lacking FDA approval and raising safety concerns.

  89. [HEALTH] 3 sources
    Retatrutide injectable cuts weight and blood sugar in phase‑3 trial for type‑2 diabetes

    Phase‑3 trial of retatrutide, a weekly triple‑hormone injectable, led by Harpreet S. Bajaj, reduced weight four‑fold and more than halved blood sugar in type‑2 diabetes patients across the US, Mexico and India.

  90. [HEALTH] 2 sources
    Ecnoglutide Shows Superior Weight Loss to Semaglutide in Chinese Clinical Trial

    Ecnoglutide cut more weight than semaglutide in a Chinese trial, showing 35% greater loss and better waist reduction, while experts stress genetic factors cause varied responses to GLP‑1 drugs.

  91. [HEALTH] 5 sources
    Boehringer Ingelheim's Survodutide Shows Strong Weight‑Loss Results but Raises Tolerability Concerns

    Survodutide achieved up to 16.6 % weight loss, 34 % visceral‑fat and 63 % liver‑fat reductions, but 19‑25 % of patients stopped treatment due to gastrointestinal side effects, sparking investor concerns.

  92. [HEALTH] 5 sources
    Eli Lilly's Retatrutide Shows Up to 28% Weight Loss in Clinical Trials

    Eli Lilly's experimental drug retatrutide cut weight up to 28% and improved diabetes markers in phase‑3 trials, but remains unapproved amid illegal sales in Brazil.

  93. [HEALTH] 2 sources
    Pfizer and Novo Nordisk present new obesity drug data at ADA conference

    Pfizer unveiled data on its experimental monthly obesity injection berobenatide, showing similar side‑effects to Wegovy and up to 15% weight loss, while Novo Nordisk’s CEO highlighted semaglutide’s potentialfor

  94. [HEALTH] 3 sources
    American Diabetes Association Conference Highlights Monthly‑Dosing Diabetes and Obesity Drugs

    ADA's June 2026 meeting presented data on monthly‑dosing triple‑G diabetes drugs and rising competition among obesity‑treatment makers, highlighting safety, clinical gaps and broader health implications.

  95. [HEALTH] 4 sources
    Eli Lilly's retatrutide cuts obesity, sleep apnea and knee pain in Phase 3 trials

    Eli Lilly's retatrutide Phase 3 trials show up to 28% weight loss, 60% reduction in sleep‑apnea severity, and major knee‑pain relief, plus A1C drops for type 2 diabetes.

  96. [BUSINESS] 2 sources
    Novo Nordisk opens Czech plant for diabetes and obesity drugs

    Novo Nordisk is opening a multi‑billion‑crown plant in Jevany, Czech Republic, to make ingredients for new diabetes and obesity drugs, amid a booming global market.

  97. [HEALTH] 2 sources
    Novo Nordisk promotes obesity awareness at Greece's BeWell Festival

    Novo Nordisk and IMEROESA highlighted obesity prevention at Athens' BeWell Festival (June 6‑7), offering BMI checks, counseling, and a panel to shift the narrative on weight management.

  98. [HEALTH] 2 sources
    Novo Nordisk launches Wegovy oral weight‑loss pill in the UAE

    Novo Nordisk has launched the oral Wegovy weight‑loss pill in the UAE, the first market outside the US, targeting the country’s high obesity rates with a drug shown to cut weight by 17 percent on average.

  99. [HEALTH] 2 sources
    Cigna to End GLP‑1 Weight‑Loss Drug Coverage for Employees

    Cigna will stop covering GLP‑1 obesity drugs such as Wegovy and Zepbound for its employee health plan on July 1, 2026, citing cost concerns while maintaining coverage for diabetes use and older weight‑loss meds

  100. [HEALTH] 6 sources
    Brazil's EMS launches first domestic semaglutide weight‑loss pen Ozivy

    EMS launches Brazil's first domestic semaglutide pen Ozivy on 15 June, priced at R$ 452 per unit with a three‑month starter pack at R$ 863.23, aiming to cut obesity‑drug costs by about 30 %.

Sources

100percentfedup.com · 247wallst · 98fmnatal.com.br · absolutegeeks.com · ac24horas.com · acapa.com.br · acessa.com · ad-hoc-news · ad-hoc-news.de · adtv.ig.com.br · aeiou.pt · aerzteblatt.de · agazetarm.com.br · ageas.com · air-conditioning.com.au · aktiencheck · aktiencheck.de · aktienkurs-orderbuch.finanznachrichten.de · alagoas24horas.com.br · allgaeuer-anzeigeblatt.de · allurantmedical.com · americanbankingnews · amica.de · amodireito.com.br · amp.bemparana.com.br · anoticiaregional.com.br · aquiacontece.com.br · aquiagora.net · archive.in.gr · archynewsy.com · arts-spectacles.com · arvopaperi.fi · arynews.tv · atarde.com.br · athleticsasia.org · atibaia.com.br · atualidadepolitica.com.br · avronline.de · azsalute.it · babadosebadalos.com.br · bamleik.no · barlettanews.it · bbv-net.de · bemparana.com.br · berliner-zeitung.de · bermudabroadcasting.com · bettinginsider.com · beverlyhillsplasticsurgeryinc.com

This summary has been updated 25 times: see revision history